Previsión
El precio objetivo medio de los analistas es de 910,05 € (-6,67 %). La mediana es de 911,35 € (-6,54 %).
| Comprar |
25 |
| Mantener |
6 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Alluvium raises McKesson stake after management reiterates 13–16% long‑term growth target
Alluvium Asset Management said it increased its position in McKesson after the drug distributor reported full‑year results in line with expectations and management reaffirmed 13–16% long‑term earnings growth. The fund’s valuation model rose about 18% versus the share price, leading McKesson to represent 6.8% of the Conventum – Alluvium Global Fund. McKesson closed at $899.56 on September 15, with a 52‑week gain near 30% and recent analyst commentary describing its FY27 outlook as "good enough." » Más en finance.yahoo.com
McKesson raises full-year outlook after oncology expansion
At the Morgan Stanley Healthcare Conference, McKesson raised its EPS outlook for 2027 to $44.20–45.00 and sees reported growth of 13–15%. Strong results in the Oncology and Multispecialty segment and expansion in oncology and biopharma services—including the planned acquisition of Precision Medicine Group—are driving the improvement. The med-surg business is under pressure, while buybacks, higher dividends and a planned spinoff of Wellverse support capital allocation and shareholder returns. » Más en de.investing.com
McKesson to buy Precision Medicine Group for $2.25 billion as oncology growth accelerates
McKesson plans to acquire Precision Medicine Group for $2.25 billion to add oncology-focused CRO, clinical-trial and market-access capabilities to its Oncology and Multi-Specialty segment, subject to regulatory approval. The company reported strong first-quarter results, with North American Pharmaceutical Distribution revenue up ~5% and Oncology and Multi-Specialty revenue and profit rising about 33% and 41%, respectively. McKesson expects to return roughly $5 billion to shareholders this year, including $2.5 billion in buybacks and a 15% dividend increase, while continuing investments in automation, AI and other growth initiatives. The firm is also progressing with the separation of its Medical-Surgical business, rebranded as Wellverse, targeted for the back half of next year. » Más en finance.yahoo.com
McKesson buys Precision Medicine Group for $2.25 billion to boost oncology
McKesson will acquire Precision Medicine Group for about $2.25 billion to expand its Oncology & Multispecialty business with clinical research, lab testing and commercialization services. The deal aligns with McKesson's strategy of exiting non-core assets and investing in higher-growth specialty and oncology areas. Management expects the acquisition to strengthen clinical trial execution and biopharma offerings, but no closing timeline was provided and integration, scalability and near-term earnings impact remain uncertain. » Más en finance.yahoo.com
McKesson buys Precision Medicine Group for $2.25 billion, strengthens oncology segment
McKesson has signed a definitive agreement to acquire Precision Medicine Group for about $2.25 billion, a move investors view as expanding its oncology and multispecialty strategy. Precision Medicine Group provides clinical research services, biomarker analysis, laboratory services and commercialization support for biotech and pharma companies. The acquisition follows a restructuring that refocused McKesson on higher-margin, faster-growing areas; its oncology and multispecialty business recently grew by 33%. analyst backing and a dividend increase have supported the positive market reaction; the stock rose sharply intraday and is approaching its 52-week high. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2026, McKesson ya ha pagado 2,97 € en dividendos. El último pago fue en octubre.
Datos financieros
En el último trimestre, McKesson tuvo unos ingresos de 97,96 mil M € y un beneficio neto de 1075,31 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 97,96 mil M | 11,45 % |
| Beneficio bruto | 3492,56 M | 15,71 % |
| Beneficio neto | 1075,31 M | 13,69 % |
| EBITDA | 1645,63 M | 16,55 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 111,76 mil M € |
Número de acciones | 115,46 M |
Máximo/mínimo de 52 semanas | 1022,08 € - 659,53 € |
Rentabilidad por dividendo | 0,30 % |
Dividendos TTM | 2,96 € |
Beta | 0,28 |
Ratio P/E | 27,20 |
Ratio PEG | 1,29 |
Ratio P/B | -31,24 |
Ratio P/S | 0,29 |
Perfil de la empresa
McKesson Corporation presta servicios sanitarios en Estados Unidos y a nivel internacional. Opera a través de cuatro segmentos: U.S. Pharmaceutical, International, Medical-Surgical Solutions y Prescription Technology Solutions (RxTS). El segmento U.S. Pharmaceutical distribuye medicamentos de marca, genéricos, de especialidad, biosimilares y de venta libre, así como otros productos relacionados con la sanidad. Este segmento también ofrece soluciones de gestión de consultas, tecnología, apoyo clínico y soluciones empresariales a consultas de oncología de base comunitaria y otras consultas especializadas; y servicios de consultoría, externalización, tecnología y otros servicios, además de vender soluciones financieras, operativas y clínicas a farmacias. El segmento International ofrece distribución y servicios a clientes mayoristas, institucionales y minoristas en 13 países europeos y en Canadá. El segmento Medical-Surgical Solutions proporciona distribución de suministros médico-quirúrgicos, logística y otros servicios a proveedores sanitarios. El segmento RxTS atiende a socios y pacientes de las empresas biofarmacéuticas y de ciencias de la vida para abordar los desafíos relacionados con la medicación de los pacientes a lo largo de sus trayectorias; conecta a farmacias, proveedores, pagadores y empresas biofarmacéuticas para ofrecer soluciones innovadoras de acceso y adherencia; y proporciona servicios de logística de terceros y soluciones de apoyo a la distribución mayorista. McKesson Corporation fue fundada en 1833 y tiene su sede en Irving, Texas.
| Nombre | McKesson |
| CEO | Brian S. Tyler |
| Sede | Irving,
tx Estados Unidos |
| Sitio web | |
| Sector | Salud |
| Industria | Proveedores y servicios sanitarios |
| Salida a bolsa | 10/11/1994 |
| Empleados | 42.300 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NYSE | MCK |
London Stock Exchange | 0JZU.L |
Frankfurt | MCK.F |
Düsseldorf | MCK.DU |
London | 0JZU.L |
SIX | MCK.SW |
München | MCK.MU |